Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma.

Ou DL, Lin YY, Hsu CL, Lin YY, Chen CW, Yu JS, Miaw SC, Hsu PN, Cheng AL, Hsu C.

Liver Cancer. 2019 May;8(3):155-171. doi: 10.1159/000489318. Epub 2018 Jun 22.

2.

Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.

Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY, Huang SM, Guo WB, Gou LY, Sun HW, Zhang Q, Xie Z, Yan LX, Su J, Yang JJ, Zhong WZ, Zhang XC, Wu YL.

J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.

3.

Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.

Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, Kwekkeboom J.

Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.

PMID:
28648905
4.

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.

Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG.

Hepatology. 2015 May;61(5):1591-602. doi: 10.1002/hep.27665. Epub 2015 Mar 20.

5.

Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.

Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J.

Oncotarget. 2017 Jun 20;8(25):41242-41255. doi: 10.18632/oncotarget.17168.

6.

Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.

Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX.

Gut. 2019 Mar 22. pii: gutjnl-2019-318419. doi: 10.1136/gutjnl-2019-318419. [Epub ahead of print]

PMID:
30902885
7.

Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma.

Kim HD, Song GW, Park S, Jung MK, Kim MH, Kang HJ, Yoo C, Yi K, Kim KH, Eo S, Moon DB, Hong SM, Ju YS, Shin EC, Hwang S, Park SH.

Gastroenterology. 2018 Dec;155(6):1936-1950.e17. doi: 10.1053/j.gastro.2018.08.030. Epub 2018 Aug 24.

PMID:
30145359
8.

Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment.

Lu LC, Lee YH, Chang CJ, Shun CT, Fang CY, Shao YY, Liu TH, Cheng AL, Hsu CH.

Liver Cancer. 2019 Mar;8(2):110-120. doi: 10.1159/000489021. Epub 2018 Jun 15.

9.

IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.

Liu H, Shen J, Lu K.

Biochem Biophys Res Commun. 2017 Apr 29;486(2):239-244. doi: 10.1016/j.bbrc.2017.02.128. Epub 2017 Mar 1.

PMID:
28254435
10.

Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.

Chen ML, Yan BS, Lu WC, Chen MH, Yu SL, Yang PC, Cheng AL.

Int J Cancer. 2014 Jan 15;134(2):319-31. doi: 10.1002/ijc.28362. Epub 2013 Jul 30.

11.

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.

Rataj F, Kraus FBT, Chaloupka M, Grassmann S, Heise C, Cadilha BL, Duewell P, Endres S, Kobold S.

Front Immunol. 2018 Aug 30;9:1955. doi: 10.3389/fimmu.2018.01955. eCollection 2018.

12.

PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.

Seifert AM, Zeng S, Zhang JQ, Kim TS, Cohen NA, Beckman MJ, Medina BD, Maltbaek JH, Loo JK, Crawley MH, Rossi F, Besmer P, Antonescu CR, DeMatteo RP.

Clin Cancer Res. 2017 Jan 15;23(2):454-465. doi: 10.1158/1078-0432.CCR-16-1163. Epub 2016 Jul 28.

13.

Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.

Guo Z, Wang H, Meng F, Li J, Zhang S.

J Transl Med. 2015 Jul 29;13:247. doi: 10.1186/s12967-015-0613-y.

14.

The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.

Li HY, McSharry M, Bullock B, Nguyen TT, Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC, Clambey ET, Nemenoff RA.

Cancer Immunol Res. 2017 Sep;5(9):767-777. doi: 10.1158/2326-6066.CIR-16-0365. Epub 2017 Aug 17.

15.

Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma.

Chang CJ, Yang YH, Chiu CJ, Lu LC, Liao CC, Liang CW, Hsu CH, Cheng AL.

Int J Cancer. 2018 May 1;142(9):1878-1889. doi: 10.1002/ijc.31216. Epub 2017 Dec 26.

16.

Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma.

Wang Y, Li H, Liang Q, Liu B, Mei X, Ma Y.

Tumour Biol. 2015 Mar;36(3):1561-6. doi: 10.1007/s13277-014-2722-2. Epub 2014 Nov 5.

PMID:
25371070
17.

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.

Qian J, Wang C, Wang B, Yang J, Wang Y, Luo F, Xu J, Zhao C, Liu R, Chu Y.

J Neuroinflammation. 2018 Oct 17;15(1):290. doi: 10.1186/s12974-018-1330-2.

18.

Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.

Takeda Y, Yoshida S, Takashima K, Ishii-Mugikura N, Shime H, Seya T, Matsumoto M.

Cancer Sci. 2018 Jul;109(7):2119-2129. doi: 10.1111/cas.13649. Epub 2018 Jun 16.

19.

PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).

Berghoff AS, Ricken G, Widhalm G, Rajky O, Hainfellner JA, Birner P, Raderer M, Preusser M.

Clin Neuropathol. 2014 Jan-Feb;33(1):42-9.

PMID:
24359606
20.

PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.

Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS.

Int J Cancer. 2011 Feb 15;128(4):887-96. doi: 10.1002/ijc.25397.

Supplemental Content

Support Center